Test Lists

  • Regression Package Testing List Page
Publisher QA3 - UPP Test
  • Regression Package Testing List Page
1 / 0

Minimally Invasive Ellipsys System Creates Fused, Permanent Vascular Access for Dialysis

October 30, 2020
By Avenu Medical
Alt Text FF - Home Screen Icon 3
Caption FF
Description FF
Share this...
  • Facebook
  • Pinterest
  • Twitter
  • Linkedin

SAN JUAN CAPISTRANO, Calif., Oct. 30, 2020 /PRNewswire/ — A new case report published in the Journal of Vascular Surgery provides one of the first known opportunities to directly visualize the permanent and fused connection (anastomosis) that is created with the minimally invasive Ellipsys® Vascular Access System. The Ellipsys System, made by Avenu Medical, creates a type of dialysis access known as a percutaneous arteriovenous fistula (pAVF) for patients with end-stage renal disease (ESRD) who require hemodialysis.

“This is the first published report of direct visualization of a matured pAVF created with the Ellipsys System,” said lead author Alexandros Mallios, MD, a vascular surgeon at Paris Saint-Joseph Hospital in Paris, France. “It was an amazing opportunity that provided first hand proof of the permanent, fused vessel anastomosis made possible by this revolutionary technology.” 

Hemodialysis requires access to the patient’s bloodstream, which is often created by establishing a permanent connection between an artery and a vein in the arm known as an arteriovenous fistula (AVF). Traditionally, fistulas are created during an open surgical procedure by suturing the artery and vein together. In contrast, the Ellipsys System uses a small needle puncture and catheter to percutaneously establish an AVF without an implant or suture, leaving the vessels and tissue around the fistula undisturbed.

The subject of the case report was an 80-year-old male diabetic ESRD patient who had a pAVF created with the Ellipsys System 6 months prior. He was evaluated for decreasing blood flow (unrelated to his fistula) and required surgical intervention, which provided the opportunity to visualize the matured Ellipsys pAVF up close. According to Dr. Mallios, the lack of sutures or other foreign bodies made the fusion look “remarkably natural.”

Dr. Mallios has published numerous studies showing the ability of the Ellipsys System to easily and safely create durable vascular access for ESRD patients. In July 2020, he reported one-year follow-up results of 234 Ellipsys patients, the largest study of any pAVF technique to date. Published in JVS, the study reported no adverse events and 96 percent of patients still had fully functioning fistulas with strong blood flow after a year. That “patency rate” is higher than published rates for surgically created fistulas, which average about 60% after one year.

In April 2020, JVS published a case report by Dr. Mallios that featured a 3-D rendering of the Ellipsys pAVF on the cover of the publication. Dr. Mallios also co-authored two recent papers in the Journal of Vascular Access that discussed patient eligibility for Ellipsys and the similarities between an Ellipsys pAVF and a surgical AVF, the current standard of care.

Recently published long-term Ellipsys data showed a functional patency rate of 92 percent at two years. The study also found high levels of patient satisfaction with the procedure.

Cleared by the FDA in 2018 for patients with end-stage renal disease, Ellipsys is the first significant innovation in AVF creation in over 50 years. It transforms a complex surgery into a minimally invasive procedure that can be performed in a hospital outpatient setting, ambulatory surgery center or physician’s office. Since 2015, nearly 3,000 patients worldwide have undergone the Ellipsys procedure.

Medtronic recently announced its plan to acquire Avenu Medical for the Ellipsys percutaneous fistula creation technology. Terms of the deal were not disclosed.

About Avenu Medical
Avenu Medical Inc. was founded in 2010 to pursue unmet clinical needs in the ESRD and vascular access markets. The company’s Ellipsys Vascular Access System is an innovative, ultrasound-guided, single-catheter endoAVF system used to percutaneously create an arteriovenous fistula for hemodialysis access. Learn more at www.avenumedical.com.

Contact: Liz Dowling
Dowling & Dennis PR
415-388-2794
Liz@dowlingdennis.net

 

Categories: Madison Magazine Logo

Latest Stories

Eu Regulator Authorizes Astrazeneca Vaccine For All Adults

EU regulator authorizes AstraZeneca vaccine for all adults

Rayos Syndication User,
KXLY-Latest Stories

Regulators authorized AstraZeneca’s coronavirus vaccine for use in adults throughout the European Union on Friday, amid criticism the bloc is not moving fast enough to vaccinate its population.

Ex Fbi Lawyer Given Probation For Russia Probe Actions

Ex-FBI lawyer given probation for Russia probe actions

Rayos Syndication User,
KXLY-Latest Stories

WASHINGTON (AP) — A former FBI lawyer was sentenced to probation for altering an email that the Justice Department relied on during its surveillance of an aide to President Donald Trump during the Russia investigation.

Evers: Repealing Mask Mandate Like Eliminating Speed Limits

Evers: Repealing mask mandate like eliminating speed limits

Rayos Syndication User,
KXLY-Latest Stories

MADISON, Wis. (AP) — Democratic Gov. Tony Evers lashed out Friday at rival Republicans who tried to repeal his statewide mask mandate, saying killing the order would be a ridiculous move comparable to abolishing speed limits.

Conservatives Praise South Carolina Win On Abortion Ban

Conservatives praise South Carolina win on abortion ban

Rayos Syndication User,
KXLY-Latest Stories

COLUMBIA, S.C. (AP) — As some conservatives in South Carolina celebrated getting a bill that would ban almost all abortions in the state past a legislative barrier and likely becoming law, they said they are not finished trying to end all abortions.

Moscow Court Puts Navalny’s Allies Under House Arrest

Moscow court puts Navalny's allies under house arrest

Rayos Syndication User,
KXLY-Latest Stories

A Moscow court on Friday put the brother and several allies of Russian opposition leader Alexei Navalny under house arrest for two months as authorities sought to stymie more protests over the jailing of the top Kremlin foe.

Most Popular

9:40 Future Import Test

One more current test NW

Current UPP Import NW

Test New Article 12092025 - 4 - Message

Test New Article 12092025 - 4 - Election

Test New Article 12092025 - 2 - Closing

© 2026 Publisher QA3 – UPP Test.

Privacy Policy
Powered byBLOX Digital
X